Fluvoxamine in the treatment of body dysmorphic disorder (dysmorphophobia)

International Clinical Psychopharmacology

Volumn 11, Issue 4, 1996, Pages 247-254

  Perugi, G ^a   Giannotti, D ^a   Di Vaio, S ^a   Frare, F ^a   Saettoni, M ^a   Cassano, G B ^a  

^a UNIVERSITY OF PISA   (Italy)

Author keywords

body dysmorphic disorder; dysmorphophobia; fluvoxamine; open trial; serotonin reuptake inhibitors; treatment

Indexed keywords

FLUVOXAMINE;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DIARRHEA; DRUG EFFICACY; DRUG TOLERANCE; FEMALE; HUMAN; HYPOCHONDRIASIS; MALE; MENTAL DISEASE; NAUSEA; PHOBIA; PRIORITY JOURNAL;

EID: 0030451973     PISSN: 02681315     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004850-199612000-00006     Document Type: Article

References (38)

1. American Psychiatric Association (1980) Diagnostic and Statistical Manual of Mental Disorders, 3rd edn. APA, Washington, DC.
2. American Psychiatric Association (1987) Diagnostic and Statistical Manual of Mental Disorders, 3rd edn, revised. APA, Washington, DC.
3. American Psychiatric Association (1994) Diagnostic and Statistical Manual of Mental Disorders, 4th edn, revised. APA, Washington, DC.
4. Andreasen NC and Bardach J (1977) Dysmorphophobia: symptom or disease? American Journal of Psychiatry, 134, 673-676.
5. Brady KT, Austin L and Lydiard RB (1990) Body dysmorphic disorder: the relationship to obsessive-compulsive disorder. Journal of Nervous and Mental Disease, 178, 538-540.
6. Cotteril JA (1981) Dermatological non-disease: a common and potentially fatal disturbance of cutaneous body image. British Journal of Dermatology, 104, 611-619.
7. Den Boer JA, Westenberg HGM, Kamerbeek WDJ, Verhoeven WMA and Kahn RS (1987) Effect of serotonin uptake inhibitors in anxiety disorders; a double-blind comparison of clomipramine and fluvoxamine. International Clinical Psychopharmacology, 2, 21-32.
8. Derogatis LR, Lipman RS and Rickels K (1973) The Hopkins Symptom Checklist (HSCL): a measure of primary symptom dimensions in psychological measurement. In: Modern Problems in Pharmacopsychiatry (Ed. P Pichot). Karger, Basle.
9. Fukuda O (1977) Statistical analysis of dysmorphophobia in outpatient clinic. Japanese Journal of Plastic and Reconstructive Surgery, 20, 569-577.
10. Goodman WK, Price LH, Rasmussen SA et al. (1989) The efficacy of fluvoxamine in obsessive-compulsive disorder: a double-blind comparison with placebo. Archives of General Psychiatry, 46, 36-44.
11. Guy W (1976) ECDEU Assessment Manual for Psychopharmacology. National Institute of Mental Health, Rockville, MD.
12. Hamilton S (1967) Development of a rating scale for primary depressive illness. British Journal of Social and Clinical Psychology, 6, 278-296.
13. Hay GG (1970) Dysmorphophobia. British Journal of Psychiatry, 116, 399-406.
14. Hollander E and Wong CM (1995) Body dysmorphic disorder, pathological gambling and sexual compulsions. Journal of Clinical Psychiatry, 56 (suppl 4), 7-12.
15. Hollander E, Liebowitz MR, Winchel R, Klumker A and Klein DF (1989) Treatment of body dysmorphic disorder with serotonin reuptake blockers. American Journal of Psychiatry, 146, 768-770.
16. Hollander E, Cohen LJ and Simeon D (1993) Body dysmorphic disorder. Psychiatric Annals, 23, 359-364.
17. Hollander E, Cohen L, Simeon D, Rosen J, DeCaria C and Stein DJ (1994) Fluvoxamine treatment of body dysmorphic disorder. Journal of Clinical Psychopharmacology, 14, 75-77.
18. Ladee GA (1966) Hypocondriacal Syndromes. Elsevier, Amsterdam.
19. McDougle CJ, Goodman WK, Price LH, Delgado PL, Krystal JH, Charney DS and Heninger GR (1990) Neuroleptic addition in fluvoxamine-refractory obsessive-compulsive disorder. American Journal of Psychiatry, 147, 652-654.
20. McElroy SL, Phillips KA and Keck PE Jr (1994) Obsessive compulsive spectrum disorder. Journal of Clinical Psychiatry, 55 (suppl 10), 35-51.
21. Montgomery SA and Manceaux A (1992) Fluvoxamine in the treatment of obsessive compulsive disorder. International Clinical Psychopharmacology, 7, 5-9.
22. Morselli E (1891) Sulla dismorfofobia e sulla tafefobia. Bollettino della Regia Accademia di Genova, 6, 110-119.
23. Munro A and Chmara J (1982) Monosymptomatic hypocondriacal psychosis: a diagnostic checklist based on 50 cases of the disorder. Canadian Journal of Psychiatry, 27, 374-376.
24. Olley PC (1974) Psychiatric aspects of referral. British Medical Journal, 3, 248-249.
25. Peveler RC and Fairburn CG (1990) Measurement of neurotic symptoms by self report questionnaire: validity of the SCL-90R. Pscyhological Medicine, 20, 873-879.
26. Phillips KA (1991) Body dysmorphic disorder: the distress of imagined ugliness. American Journal of Psychiatry, 148, 1138-1149.
27. Phillips KA (1995) Body dysmorphic disorder: clinical features and drug treatment. CNS Drugs, 3, 30-40.
28. Phillips KA, McElroy SL, Keck PE Jr, Pope HG Jr and Hudson JI (1993) Body dysmorphic disorder: 30 cases of imagined ugliness. American Journal of Psychiatry, 150, 302-308.
29. Phillips KA, McElroy SL, Keck PE Jr, Hudson JI and Pope HG Jr (1994) A comparison of delusional and nondelusional body dysmorphic disorder in 100 cases. Psychopharmacology Bulletin, 30, 179-186.
30. Phillips KA, McElroy SL, Hudson JI and Pope HG Jr (1995) Body dysmorphic disorder: an obsessive-compulsive spectrum disorder, a form of affective spectrum disorder, or both? Journal of Clinical Psychiatry, 56 (suppl 4), 41-51.
31. Pigott TA, L'Heureux F, Dubbert B, Bernstein S and Murphy DL (1994) Obsessive compulsive disorder: comorbid conditions. Journal of Clinical Psychiatry, 55 (suppl 10), 15-27.
32. Vallat JN, Leger JM, Destruhaut J and Garoux R (1971) Dysmorphophobie: syndrome au symptome? Annales Medico-Psychologiques, 2, 45-65.
33. van Vliet IM, den Boer JA and Westenberg HGM (1993) Psychopharmacological treatment of Social Phobia; a double blind placebo controlled study with fluvoxamine. Psychopharmachology, 115, 128-134.
34. von Haustein UF and Seikowski K (1988) Dysmorphophobie-Bewahrungsfeld zwischen Dermatologen und Psychotherapeuten. Dermatologische Monatsschrift, 174, 345-348.
35. Wagner W, Plekkenpol B, Gray TE, Vlaskamp H and Essers H (1992) Review of fluvoxamine safety database. Drugs, 43, 48-54.
36. Wilde MI, Plosker GL and Benfield P (1993) Fluvoxamine. An updated review of its pharmacology, and therapeutic use in depressive illness. Drugs, 46, 895-924.
37. World Health Organization (1992) International Classification of Diseases, 10th edn. WHO, Geneva.
38. Zaidens SH (1950) Dermatological hypocondriasis: a form of schizophrenia. Psychosomatic Medicine, 12, 250-253.